These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12975604)

  • 1. Role of perlecan in skeletal development and diseases.
    Hassell J; Yamada Y; Arikawa-Hirasawa E
    Glycoconj J; 2002; 19(4-5):263-7. PubMed ID: 12975604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of perlecan in neuromuscular function: studies in knockout mice and human disorders].
    Hirasawa E
    Tanpakushitsu Kakusan Koso; 2004 Nov; 49(15 Suppl):2425-30. PubMed ID: 15552996
    [No Abstract]   [Full Text] [Related]  

  • 3. Schwartz-Jampel syndrome and perlecan deficiency.
    Stum M; Davoine CS; Fontaine B; Nicole S
    Acta Myol; 2005 Oct; 24(2):89-92. PubMed ID: 16550923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Roles of perlecan in development and disease: studies in knockout mice and human disorders].
    Arikawa-Hirasawa E; Yamada Y
    Seikagaku; 2001 Oct; 73(10):1257-61. PubMed ID: 11725543
    [No Abstract]   [Full Text] [Related]  

  • 5. Perlecan functions in chondrogenesis: insights from in vitro and in vivo models.
    Gomes RR; Farach-Carson MC; Carson DD
    Cells Tissues Organs; 2004; 176(1-3):79-86. PubMed ID: 14745237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene.
    Arikawa-Hirasawa E; Wilcox WR; Le AH; Silverman N; Govindraj P; Hassell JR; Yamada Y
    Nat Genet; 2001 Apr; 27(4):431-4. PubMed ID: 11279527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyssegmental dysplasia, Silverman-Handmaker type: unexpected role of perlecan in cartilage development.
    Arikawa-Hirasawa E; Wilcox WR; Yamada Y
    Am J Med Genet; 2001; 106(4):254-7. PubMed ID: 11891676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of the pericellular matrix molecule perlecan lowers in situ cell and matrix stiffness in developing cartilage.
    Xu X; Li Z; Leng Y; Neu CP; Calve S
    Dev Biol; 2016 Oct; 418(2):242-7. PubMed ID: 27578148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mouse model of Schwartz-Jampel syndrome reveals myelinating Schwann cell dysfunction with persistent axonal depolarization in vitro and distal peripheral nerve hyperexcitability when perlecan is lacking.
    Bangratz M; Sarrazin N; Devaux J; Zambroni D; Echaniz-Laguna A; René F; Boërio D; Davoine CS; Fontaine B; Feltri ML; Benoit E; Nicole S
    Am J Pathol; 2012 May; 180(5):2040-55. PubMed ID: 22449950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perlecan Knockdown Significantly Alters Extracellular Matrix Composition and Organization During Cartilage Development.
    Ocken AR; Ku MM; Kinzer-Ursem TL; Calve S
    Mol Cell Proteomics; 2020 Jul; 19(7):1220-1235. PubMed ID: 32381549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia.
    Arikawa-Hirasawa E; Le AH; Nishino I; Nonaka I; Ho NC; Francomano CA; Govindraj P; Hassell JR; Devaney JM; Spranger J; Stevenson RE; Iannaccone S; Dalakas MC; Yamada Y
    Am J Hum Genet; 2002 May; 70(5):1368-75. PubMed ID: 11941538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the heparan sulfate proteoglycan perlecan on human disease and health.
    Arikawa-Hirasawa E
    Am J Physiol Cell Physiol; 2022 Jun; 322(6):C1117-C1122. PubMed ID: 35417267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on molecules: perlecan (HSPG2).
    Smith S; Hassell JR
    Exp Eye Res; 2006 Sep; 83(3):471-2. PubMed ID: 16549064
    [No Abstract]   [Full Text] [Related]  

  • 14. Ablation of Perlecan Domain 1 Heparan Sulfate Reduces Progressive Cartilage Degradation, Synovitis, and Osteophyte Size in a Preclinical Model of Posttraumatic Osteoarthritis.
    Shu CC; Jackson MT; Smith MM; Smith SM; Penm S; Lord MS; Whitelock JM; Little CB; Melrose J
    Arthritis Rheumatol; 2016 Apr; 68(4):868-79. PubMed ID: 26636652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of collagen type II and perlecan in skeletal development.
    Gustafsson E; Aszodi A; Ortega N; Hunziker EB; Denker HW; Werb Z; Fassler R
    Ann N Y Acad Sci; 2003 May; 995():140-50. PubMed ID: 12814946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparan sulfate: lessons from knockout mice.
    Forsberg E; Kjellén L
    J Clin Invest; 2001 Jul; 108(2):175-80. PubMed ID: 11457868
    [No Abstract]   [Full Text] [Related]  

  • 17. Heparan sulfate proteoglycans: key players in cartilage biology.
    Farach-Carson MC; Hecht JT; Carson DD
    Crit Rev Eukaryot Gene Expr; 2005; 15(1):29-48. PubMed ID: 15831077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the basement membrane heparan sulfate proteoglycan (perlecan) in human synovium and in cultured human synovial cells.
    Dodge GR; Boesler EW; Jimenez SA
    Lab Invest; 1995 Nov; 73(5):649-57. PubMed ID: 7474938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of perlecan, a proteoglycan that binds myogenic inhibitory basic fibroblast growth factor, is down regulated during skeletal muscle differentiation.
    Larraín J; Alvarez J; Hassell JR; Brandan E
    Exp Cell Res; 1997 Aug; 234(2):405-12. PubMed ID: 9260911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perlecan is essential for cartilage and cephalic development.
    Arikawa-Hirasawa E; Watanabe H; Takami H; Hassell JR; Yamada Y
    Nat Genet; 1999 Nov; 23(3):354-8. PubMed ID: 10545953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.